Type i interferon responses in rhesus macaques prevent SIV infection and slow disease progression

Nature

Volumn 511, Issue 7511, 2014, Pages 601-605

  Sandler, Netanya G ^a,g   Bosinger, Steven E ^b   Estes, Jacob D ^c   Zhu, Richard T R ^a   Tharp, Gregory K ^b   Boritz, Eli ^a   Levin, Doron ^d   Wijeyesinghe, Sathi ^a   Makamdop, Krystelle Nganou ^a   Del Prete, Gregory Q ^c   Hill, Brenna J ^a   Timmer, J Katherina ^a   Reiss, Emma ^a   Yarden, Ganit ^d   Darko, Samuel ^a   Contijoch, Eduardo ^a   Todd, John Paul ^a   Silvestri, Guido ^b   Nason, Martha ^a   Norgren Jr , Robert B ^e   Keele, Brandon F ^c   Rao, Srinivas ^a   Langer, Jerome A ^f   Lifson, Jeffrey D ^c   Schreiber, Gideon ^d   Douek, Daniel C ^a   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EMORY UNIVERSITY   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERFERON; INTERFERON RECEPTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; DISEASE COURSE; GENE EXPRESSION; IN VIVO STUDY; INFECTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; MACACA MULATTA; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84901933676     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13554     Document Type: Article

References (30)

1. Hunt, P. W. et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiu238 (21 April 2014).
2. Roberts, L. et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J. Infect. Dis. 205, 194-203 (2012).
3. Naranbhai, V. et al. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J. Infect. Dis. 206, 993-1001 (2012).
4. Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485 (2011).
5. Schoggins, J. W. et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505, 691-695 (2013).
6. Gonzalez-Navajas, J. M.,Lee, J.,David,M. & Raz, E.Immunomodulatory functions of type I interferons. Nature Rev. Immunol. 12, 125-135 (2012).
7. Lane, H. C. et al. Anti-retroviral effects of interferon-a in AIDS-associated Kaposi's sarcoma. Lancet 332, 1218-1222 (1988).
8. Manion, M. et al. Interferon-alpha administration enhances CD81T cell activation in HIV infection. PLoS ONE 7, e30306 (2012).
9. Azzoni, L. et al. Pegylated Interferon alfa-2amonotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIVDNA integration. J. Infect. Dis. 207, 213-222 (2013).
10. Feld, J. J. & Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967-972 (2005).
11. Stacey, A. R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719-3733 (2009).
12. Fraietta, J. A. et al. Type I interferon upregulates Bak and contributes to T cell loss during humanimmunodeficiency virus (HIV) infection. PLoS Pathog. 9, e1003658 (2013).
13. Abel, K. et al. The relationship between simian immunodeficiency virus RNA levels andthemRNAlevels of a/b interferons (IFN-alpha/beta) and IFN-a/b-inducibleMx in lymphoid tissues of rhesus macaques during acute and chronic infection. J. Virol. 76, 8433-8445 (2002).
14. Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207-211 (2013).
15. Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202-207 (2013).
16. Li, Q. et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038 (2009).
17. Haas, D. W. et al. A randomized trial of interferon alpha therapy for HIV type 1 infection. AIDS Res. Hum. Retroviruses 16, 183-190 (2000).
18. Fernandez, S. et al. CD41 T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferonstimulated genes in CD41 T cells. J. Infect. Dis. 204, 1927-1935 (2011).
19. Levin, D. et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 7, ra50 (2014).
20. Goujon, C. et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502, 559-562 (2013).
21. Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772-777 (2005).
22. Barouch, D. H. et al. Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
23. Carrington, M.& Alter, G. Innate immune control of HIV. Cold Spring Harb. Perspect. Med. 2, a007070 (2012).
24. Asmuth, D. M. et al. Pegylated interferon-a 2a treatment of chronic SIV-infected macaques. J. Med. Primatol. 37, 26-30 (2008).
25. Litvak, V. et al. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490, 421-425 (2012).
26. Schellekens, H. et al. The effect of recombinant human interferon aB/D compared to interferon a2b on SIV infection in rhesus macaques. Antiviral Res. 32, 1-8 (1996).
27. Waggoner, S. N., Daniels, K. A. & Welsh, R. M. Therapeutic depletion of natural killer cells controls persistent infection. J. Virol. 88, 1953-1960 (2014).
28. Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl Acad. Sci. USA 110, 6626-6633 (2013).
29. Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10, 146 (2013).
30. McElrath, M. J. et al. Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. J. Acquir. Immune Defic. Syndr. 63, 263-271 (2013).